{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T23:21:19Z","timestamp":1787872879723,"version":"build-2784847793"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Biofidelity Ltd"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-57421-5","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T13:14:23Z","timestamp":1781356463000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enrichment of mutated DNA enables ultra-sensitive ctDNA detection in NSCLC using shallow targeted sequencing"],"prefix":"10.1038","volume":"16","author":[{"given":"Paul","family":"Labrousse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Stetson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina K.","family":"Powalowska-Pickton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna A.","family":"Anton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Litovchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Lowy-Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Lovell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Hackinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Stolarek-Januszkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barnaby W.","family":"Balmforth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hadfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"issue":"302","key":"57421_CR1","doi-asserted-by":"publisher","first-page":"302ra133","DOI":"10.1126\/scitranslmed.aab0021","volume":"7","author":"I Garcia-Murillas","year":"2015","unstructured":"Garcia-Murillas, I. et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci. Transl Med. 7 (302), 302ra133. https:\/\/doi.org\/10.1126\/scitranslmed.aab0021 (2015).","journal-title":"Sci. Transl Med."},{"issue":"6","key":"57421_CR2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.annonc.2025.01.021","volume":"36","author":"I Garcia-Murillas","year":"2025","unstructured":"Garcia-Murillas, I. et al. Whole genome sequencing powered ctDNA sequencing for breast cancer detection. Ann. Oncol. 36 (6), 673\u2013681. https:\/\/doi.org\/10.1016\/j.annonc.2025.01.021 (2025).","journal-title":"Ann. Oncol."},{"issue":"24","key":"57421_CR3","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/nejmoa2200075","volume":"386","author":"J Tie","year":"2022","unstructured":"Tie, J. et al. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. N Engl. J. Med. 386 (24), 2261\u20132272. https:\/\/doi.org\/10.1056\/nejmoa2200075 (2022).","journal-title":"N Engl. J. Med."},{"issue":"1","key":"57421_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41591-024-03216-y","volume":"31","author":"JRM Black","year":"2025","unstructured":"Black, J. R. M. et al. Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma. Nat. Med. 31 (1), 70\u201376. https:\/\/doi.org\/10.1038\/s41591-024-03216-y (2025).","journal-title":"Nat. Med."},{"issue":"1","key":"57421_CR5","doi-asserted-by":"publisher","first-page":"6770","DOI":"10.1038\/s41467-021-27022-z","volume":"12","author":"B Qiu","year":"2021","unstructured":"Qiu, B. et al. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Nat. Commun. 12 (1), 6770. https:\/\/doi.org\/10.1038\/s41467-021-27022-z (2021).","journal-title":"Nat. Commun."},{"issue":"12","key":"57421_CR6","doi-asserted-by":"publisher","first-page":"CD","DOI":"10.1158\/2159-8290.cd-17-0716","volume":"7","author":"AA Chaudhuri","year":"2017","unstructured":"Chaudhuri, A. A. et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 7 (12), CD\u201317. https:\/\/doi.org\/10.1158\/2159-8290.cd-17-0716 (2017).","journal-title":"Cancer Discov"},{"issue":"7867","key":"57421_CR7","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","volume":"595","author":"T Powles","year":"2021","unstructured":"Powles, T. et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 595 (7867), 432\u2013437. https:\/\/doi.org\/10.1038\/s41586-021-03642-9 (2021).","journal-title":"Nature"},{"key":"57421_CR8","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3389\/fonc.2020.00466","volume":"10","author":"H Cao","year":"2020","unstructured":"Cao, H. et al. Circulating Tumor DNA Is Capable of Monitoring the Therapeutic Response and Resistance in Advanced Colorectal Cancer Patients Undergoing Combined Target and Chemotherapy. Front. Oncol. 10, 466. https:\/\/doi.org\/10.3389\/fonc.2020.00466 (2020).","journal-title":"Front. Oncol."},{"issue":"7957","key":"57421_CR9","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","volume":"616","author":"C Abbosh","year":"2023","unstructured":"Abbosh, C. et al. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature 616 (7957), 553\u2013562. https:\/\/doi.org\/10.1038\/s41586-023-05776-4 (2023).","journal-title":"Nature"},{"issue":"5","key":"57421_CR10","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nm.3519","volume":"20","author":"AM Newman","year":"2014","unstructured":"Newman, A. M. et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20 (5), 548\u2013554. https:\/\/doi.org\/10.1038\/nm.3519 (2014).","journal-title":"Nat. Med."},{"issue":"9","key":"57421_CR11","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/s43018-020-0096-5","volume":"1","author":"SV Bratman","year":"2020","unstructured":"Bratman, S. V. et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat. Cancer. 1 (9), 873\u2013881. https:\/\/doi.org\/10.1038\/s43018-020-0096-5 (2020).","journal-title":"Nat. Cancer"},{"issue":"8","key":"57421_CR12","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/s41416-022-01716-7","volume":"126","author":"S Flach","year":"2022","unstructured":"Flach, S. et al. Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma. Br. J. Cancer. 126 (8), 1186\u20131195. https:\/\/doi.org\/10.1038\/s41416-022-01716-7 (2022).","journal-title":"Br. J. Cancer"},{"issue":"7859","key":"57421_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41586-021-03477-4","volume":"593","author":"F Abascal","year":"2021","unstructured":"Abascal, F. et al. Somatic mutation landscapes at single-molecule resolution. Nature 593 (7859), 405\u2013410. https:\/\/doi.org\/10.1038\/s41586-021-03477-4 (2021).","journal-title":"Nature"},{"issue":"12","key":"57421_CR14","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","volume":"39","author":"DM Kurtz","year":"2021","unstructured":"Kurtz, D. M. et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat. Biotechnol. 39 (12), 1537\u20131547. https:\/\/doi.org\/10.1038\/s41587-021-00981-w (2021).","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"57421_CR15","doi-asserted-by":"publisher","first-page":"200","DOI":"10.18632\/oncotarget.28565","volume":"15","author":"J Northcott","year":"2024","unstructured":"Northcott, J. et al. Analytical validation of NeXT Personal\u00ae, an ultra-sensitive personalized circulating tumor DNA assay. Oncotarget 15 (1), 200\u2013218. https:\/\/doi.org\/10.18632\/oncotarget.28565 (2024).","journal-title":"Oncotarget"},{"issue":"17","key":"57421_CR16","doi-asserted-by":"publisher","first-page":"gkaf910","DOI":"10.1093\/nar\/gkaf910","volume":"53","author":"KA Anton","year":"2025","unstructured":"Anton, K. A. et al. Enspyre: a novel enrichment technology for selected DNA variants using pyrophosphorolysis. Nucleic Acids Res. 53 (17), gkaf910. https:\/\/doi.org\/10.1093\/nar\/gkaf910 (2025).","journal-title":"Nucleic Acids Res."},{"issue":"23","key":"57421_CR17","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1200\/jco.23.02301","volume":"42","author":"D Stetson","year":"2024","unstructured":"Stetson, D. et al. Next-Generation Molecular Residual Disease Assays: Do We Have the Tools to Evaluate Them Properly? J. Clin. Oncol. 42 (23), 2736\u20132740. https:\/\/doi.org\/10.1200\/jco.23.02301 (2024).","journal-title":"J. Clin. Oncol."},{"key":"57421_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.12688\/f1000research.16665.2","volume":"9","author":"M Garcia","year":"2020","unstructured":"Garcia, M. et al. Sarek: A portable workflow for whole-genome sequencing analysis of germline and somatic variants. F1000Research 9, 63. https:\/\/doi.org\/10.12688\/f1000research.16665.2 (2020).","journal-title":"F1000Research"},{"key":"57421_CR19","unstructured":"O\u2019Connor, B. D. & van der Auwera, G. Genomics in the Cloud: Using Docker, GATK, and WDL in Terra. First Edition (O\u2019Reilly Media, 2020)."},{"issue":"8","key":"57421_CR20","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","volume":"15","author":"S Kim","year":"2017","unstructured":"Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat. Methods. 15 (8), 591\u2013594. https:\/\/doi.org\/10.1038\/s41592-018-0051-x (2017).","journal-title":"Nat. Methods"},{"issue":"14","key":"57421_CR21","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25 (14), 1754\u20131760. https:\/\/doi.org\/10.1093\/bioinformatics\/btp324 (2009).","journal-title":"Bioinformatics"},{"issue":"5","key":"57421_CR22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","volume":"18","author":"M Ignatiadis","year":"2021","unstructured":"Ignatiadis, M., Sledge, G. W. & Jeffrey, S. S. Liquid biopsy enters the clinic \u2014 implementation issues and future challenges. Nat. Rev. Clin. Oncol. 18 (5), 297\u2013312. https:\/\/doi.org\/10.1038\/s41571-020-00457-x (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"57421_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","volume":"29","author":"D Kotani","year":"2023","unstructured":"Kotani, D. et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat. Med. 29 (1), 127\u2013134. https:\/\/doi.org\/10.1038\/s41591-022-02115-4 (2023).","journal-title":"Nat. Med."},{"issue":"9","key":"57421_CR24","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.annonc.2025.05.533","volume":"36","author":"J Mayadev","year":"2025","unstructured":"Mayadev, J. et al. Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses. Ann. Oncol. 36 (9), 1047\u20131057. https:\/\/doi.org\/10.1016\/j.annonc.2025.05.533 (2025).","journal-title":"Ann. Oncol."},{"issue":"13","key":"57421_CR25","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/nejmoa1213261","volume":"368","author":"D Sarah-Jane","year":"2013","unstructured":"Sarah-Jane, D. et al. Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer. N Engl. J. Med. 368 (13), 1199\u20131209. https:\/\/doi.org\/10.1056\/nejmoa1213261 (2013).","journal-title":"N Engl. J. Med."},{"issue":"3","key":"57421_CR26","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s43018-020-0043-5","volume":"1","author":"DW Cescon","year":"2020","unstructured":"Cescon, D. W., Bratman, S. V., Chan, S. M. & Siu, L. L. Circulating tumor DNA and liquid biopsy in oncology. Nat. Cancer. 1 (3), 276\u2013290. https:\/\/doi.org\/10.1038\/s43018-020-0043-5 (2020).","journal-title":"Nat. Cancer"},{"issue":"1","key":"57421_CR27","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12916-018-1157-9","volume":"16","author":"C Fiala","year":"2018","unstructured":"Fiala, C. & Diamandis, E. P. Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection. BMC Med. 16 (1), 166. https:\/\/doi.org\/10.1186\/s12916-018-1157-9 (2018).","journal-title":"BMC Med."},{"issue":"5","key":"57421_CR28","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/s1470-2045(25)00139-1","volume":"26","author":"MM Syeda","year":"2025","unstructured":"Syeda, M. M. et al. Clinical validation of droplet digital PCR assays in detecting BRAF V600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial. Lancet Oncol. 26 (5), 641\u2013653. https:\/\/doi.org\/10.1016\/s1470-2045(25)00139-1 (2025).","journal-title":"Lancet Oncol."},{"issue":"9","key":"57421_CR29","doi-asserted-by":"publisher","first-page":"oyaf204","DOI":"10.1093\/oncolo\/oyaf204","volume":"30","author":"AR de Abreu","year":"2025","unstructured":"de Abreu, A. R. et al. Circulating Tumor DNA detection in cancer: a comprehensive overview of current detection methods and prospects. Oncol 30 (9), oyaf204. https:\/\/doi.org\/10.1093\/oncolo\/oyaf204 (2025).","journal-title":"Oncol"},{"key":"57421_CR30","unstructured":"Brittain, B. Guardant Health Owes $83.4 Mln in DNA Sequencing Patent Case, US Jury Says. Thomson Reuters; Accessed October 29, 2025. https:\/\/www.reuters.com\/legal\/litigation\/guardant-health-owes-834-mln-dna-sequencing-patent-case-us-jury-says-2023-11-15\/ (2023)."},{"issue":"3","key":"57421_CR31","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/annonc\/mdy552","volume":"30","author":"C Abbosh","year":"2019","unstructured":"Abbosh, C., Swanton, C. & Birkbak, N. J. Clonal haematopoiesis: a source of biological noise in cell-free DNA analyses. Ann. Oncol. 30 (3), 358\u2013359. https:\/\/doi.org\/10.1093\/annonc\/mdy552 (2019).","journal-title":"Ann. Oncol."},{"issue":"1","key":"57421_CR32","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41698-025-01084-4","volume":"9","author":"DA Ruiz-Torres","year":"2025","unstructured":"Ruiz-Torres, D. A. et al. Personalized circulating tumor DNA dynamics inform survival and response to immune checkpoint blockade in recurrent\/metastatic head and neck cancer. npj Precis Oncol. 9 (1), 298. https:\/\/doi.org\/10.1038\/s41698-025-01084-4 (2025).","journal-title":"npj Precis Oncol."},{"issue":"6","key":"57421_CR33","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s40291-023-00670-1","volume":"27","author":"J Zhao","year":"2023","unstructured":"Zhao, J. et al. Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors. Mol. Diagn. Ther. 27 (6), 753\u2013768. https:\/\/doi.org\/10.1007\/s40291-023-00670-1 (2023).","journal-title":"Mol. Diagn. Ther."},{"issue":"1","key":"57421_CR34","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41698-026-01309-0","volume":"10","author":"S Flach","year":"2026","unstructured":"Flach, S. et al. Personalized ctDNA analysis for detection of residual disease and recurrence in surgically treated HNSCC patients. npj Precis Oncol. 10 (1), 103. https:\/\/doi.org\/10.1038\/s41698-026-01309-0 (2026).","journal-title":"npj Precis Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57421-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57421-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57421-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T23:15:52Z","timestamp":1787872552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57421-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["57421"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-57421-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors KAA, PKP-P, EL-G, AL, ML, SH, MS-J, and BWB were employed by the company Biofidelity Ltd at the time of the study, a privately held company, and hold stock or stock options. PL, HR, DS and JH were employed by AstraZeneca at the time of the study and hold stock in the company. Biofidelity Ltd holds patents relating to the work presented here.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"27016"}}